{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:45:15Z","timestamp":1780983915329,"version":"3.54.1"},"reference-count":9,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T00:00:00Z","timestamp":1289260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Glutamate is a major excitatory neurotransmitter, while \u03b3-aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter in the central nervous system. This GABA-glutamate imbalance is thought to play a role in the development of anxiety. Acamprosate calcium is thought to restore this chemical imbalance in alcohol withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To examine acamprosate calcium as augmentation therapy for treatment of anxiety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This 8-week, open-label study was designed to evaluate patients with anxiety who were stable on current medications (selective serotonin-reuptake inhibitors and serotonin-norepinephrine-reuptake inhibitors) but still symptomatic. Acamprosate was dosed at 1998 mg\/day. Assessments included the Hamilton Rating Scale for Anxiety (HAM-A) and the Hospital Anxiety and Depression Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirteen patients enrolled in the study and received study medication. Acamprosate reduced anxiety symptoms (mean HAM-A score reduction to 8.87 from a baseline of 20). Sixty-two percent of patients receiving acamprosate achieved remission (HAM-A score \u22647). Modal dose was 1998 mg\/day (range 999-1998). The most commonly reported adverse events were nausea (n = 1), gastrointestinal upset (n = 1), and increased dream activity (n = 1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Acamprosate calcium may be effective augmentation therapy in patients with treatment-resistant anxiety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1p353","type":"journal-article","created":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T22:39:45Z","timestamp":1289342385000},"page":"1930-1932","source":"Crossref","is-referenced-by-count":14,"title":["Acamprosate Calcium as Augmentation Therapy for Anxiety Disorders"],"prefix":"10.1177","volume":"44","author":[{"given":"Thomas L","family":"Schwartz","sequence":"first","affiliation":[{"name":"Psychiatry Department, State University of New York (SUNY) Upstate Medical University, Syracuse, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar A","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, SUNY Upstate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafi","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, SUNY Upstate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Costello","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, SUNY Upstate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2010,11,9]]},"reference":[{"key":"bibr1-aph.1P353","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.2.115"},{"key":"bibr2-aph.1P353","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00220-6"},{"key":"bibr3-aph.1P353","doi-asserted-by":"publisher","DOI":"10.1080\/10401230591002138"},{"key":"bibr4-aph.1P353","doi-asserted-by":"publisher","DOI":"10.1042\/BST0371317"},{"key":"bibr5-aph.1P353","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900010427"},{"key":"bibr6-aph.1P353","doi-asserted-by":"publisher","DOI":"10.1080\/10550490701756120"},{"key":"bibr7-aph.1P353","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519050-00006"},{"key":"bibr8-aph.1P353","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.08l00714"},{"key":"bibr9-aph.1P353","volume-title":"Campral (acamprosate calcium)","author":"Product information.","year":"2005"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1P353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1P353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:16Z","timestamp":1777374436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1P353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,9]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1345\/aph.1P353"],"URL":"https:\/\/doi.org\/10.1345\/aph.1p353","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,9]]}}}